Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Evaluating Acute Myeloid Leukemia Induction Regimens in Elderly Patients with Unfavorable Risk Cytogenetics That Are Candidates for Intensive Remission Therapy

Monica Tadros, PharmD, Guenther Koehne, MDPhD, Talia Zahra, MD, Jessica Unzaga, PharmD, Moe Shwin, Nicholas Chow

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-141276

Published: 2020

Journal Articles

Adoptive T-Cell Therapy with 3 rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant

Susan Prockop, MD, Ekaterina Doubrovina, MD PhD, Irene Rodriguez-Sanchez, Aisha N. Hasan, MD, Juliet Barker, MBBS, H.R. Castro-Malaspina, MD, Parastoo B. Dahi, MD, Sergio A. Giralt, MD, Boglarka Gyurkocza, MD, Nancy A. Kernan, MD, Guenther Koehne, MDPhD, Esperanza B. Papadopoulos, MD, Doris Ponce, MD, Craig S. Sauter, MD, Virginia Escobedo, RN, Victoria Szenes, PNP, Karim Baroudy, BS, Alison Slocum, MA, Richard J. O'Reilly, MD

Blood (2017) 130 (Supplement 1): 747.

https://doi.org/10.1182/blood.V130.Suppl_1.747.747

Published: 2017

Journal Articles

MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

Neha Korde, MD, Sham Mailankody, MBBS, Eric L Smith, MDPhD, Nikoletta Lendvai, MD PhD, Hani Hassoun, MD, Alexander Lesokhin, MD, Malin Hultcrantz, MD, David J. Chung, MDPhD, Gunjan L. Shah, MD, Guenther Koehne, MDPhD, Heather Landau, MD, Mikhail Roshal, MDPhD, Ahmet Dogan, MD PhD, Sergio A. Giralt, MD, Donna Mastey, RN, Nicole Evancha, Sean M. Devlin, PhD, Ola Landgren, MD PhD

Blood (2017) 130 (Supplement 1): 3133.

https://doi.org/10.1182/blood.V130.Suppl_1.3133.3133

Published: 2017

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Benefits Patients with Persistent Disease and Results in a High Rate of Residual Disease Clearance

Bartlomiej Getta, FRCPA, FRACP, MBBS, Mikhail Roshal, MDPhD, Guenther Koehne, MDPhD

Blood (2017) 130 (Supplement 1): 2001.

https://doi.org/10.1182/blood.V130.Suppl_1.2001.2001

Published: 2017

Journal Articles

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Gunjan L. Shah, MD, Andrew Lin, PharmD, Ryan Schofield, MS, Caitlin Sarubbi, AB, Elaina V. Preston, PA-C,MPH, Sean M. Devlin, PhD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Elizabeth Hoover, BS, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD, Heather Landau, MD

Blood (2017) 130 (Supplement 1): 2023.

https://doi.org/10.1182/blood.V130.Suppl_1.2023.2023

Published: 2017

Journal Articles

Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

Gunjan L. Shah, MD, Heather Landau, MD, Caitlin Sarubbi, A.B, Ryan Schofield, MS, Andrew Lin, PharmD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Sean M. Devlin, PhD, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD

Blood (2017) 130 (Supplement 1): 3296.

https://doi.org/10.1182/blood.V130.Suppl_1.3296.3296

Published: 2017

Journal Articles

Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches

Guenther Koehne, MDPhD, Satyajit Kosuri, MD, Ekaterina Doubrovina, MD PhD, Tao Dao, PhD, Andrew Scott, Achim A Jungbluth, MD, Richard J O'Reilly, MD

Blood (2015) 126 (23): 98.

https://doi.org/10.1182/blood.V126.23.98.98

Published: 2015

Journal Articles

Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy

Nikoletta Lendvai, MDPhD, Sean Devlin, PhD, Minal Patel, BA, Kristina Marie Knapp, Daniel Ekman, Ida Grundberg, David J Chung, MDPhD, Hani Hassoun, MD, Guenther Koehne, MDPhD, Alexander M. Lesokhin, MD, Heather Landau, MD, Sergio A. Giralt, MD, Neha S Korde, MD, Ola Landgren, MD PhD

Blood (2015) 126 (23): 4257.

https://doi.org/10.1182/blood.V126.23.4257.4257

Published: 2015

Journal Articles

Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma

Gasmi Billel, MD, Eric L Smith, MD PhD, Ahmet Dogan, MD PhD, Meier Hsu, MS, Sean Devlin, PhD, Janine D. Pichardo, BS, David J Chung, MDPhD, Guenther Koehne, MDPhD, Neha S Korde, MD, Heather J Landau, MD, Sergio A. Giralt, MD, Ola Landgren, MD PhD, Hani Hassoun, MD, Alexander M. Lesokhin, MD

Blood (2015) 126 (23): 1785.

https://doi.org/10.1182/blood.V126.23.1785.1785

Published: 2015

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents

Gunjan L Shah, MDMS, Meier Hsu, MS, Sean Devlin, PhD, David J Chung, MDPhD, Hani Hassoun, MD, Guenther Koehne, MDPhD, Neha S Korde, MD, Nikoletta Lendvai, MD PhD, Alexander M. Lesokhin, MD, Ola Landgren, MD PhD, Heather Landau, MD, Sergio A. Giralt, MD

Blood (2015) 126 (23): 1996.

https://doi.org/10.1182/blood.V126.23.1996.1996

Published: 2015

NARROW

Evaluating Acute Myeloid Leukemia Induction Regimens in Elderly Patients with Unfavorable Risk Cytogenetics That Are Candidates for Intensive Remission Therapy

Adoptive T-Cell Therapy with 3 rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant

MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Benefits Patients with Persistent Disease and Results in a High Rate of Residual Disease Clearance

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches

Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy

Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma

Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only